PriceTargets.com logo

ACADIA Pharmaceuticals - ACAD Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $25.60
  • Forecasted Upside: 51.75%
  • Number of Analysts: 16
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$16.87 As of 12/20/2024 06:15 PM ET
▲ +0.14 (0.84%)

This chart shows the closing price for ACAD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ACADIA Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACAD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACAD

Analyst Price Target is $25.60
▲ +51.75% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is $25.60, with a high forecast of $42.00 and a low forecast of $19.00. The average price target represents a 51.75% upside from the last price of $16.87.

This chart shows the closing price for ACAD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 16 investment analysts is to moderate buy stock in ACADIA Pharmaceuticals. This rating has held steady since September 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
11/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
10/10/2024Raymond JamesReiterated RatingMarket Perform
8/8/2024CitigroupLower TargetBuy ➝ Buy$30.00 ➝ $23.00
8/8/2024UBS GroupLower TargetBuy ➝ Buy$25.00 ➝ $23.00
8/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
8/7/2024Needham & Company LLCLower TargetBuy ➝ Buy$30.00 ➝ $28.00
8/7/2024Cantor FitzgeraldLower TargetOverweight ➝ Overweight$37.00 ➝ $28.00
8/7/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$29.00 ➝ $26.00
8/7/2024Morgan StanleyDowngradeOverweight ➝ Equal Weight$28.00 ➝ $20.00
7/12/2024Morgan StanleyLower TargetOverweight ➝ Overweight$30.00 ➝ $28.00
6/27/2024BMO Capital MarketsInitiated CoverageOutperform$31.00
6/25/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$29.00 ➝ $29.00
5/10/2024Bank of AmericaLower TargetNeutral ➝ Neutral$26.00 ➝ $22.00
5/9/2024HC WainwrightLower TargetBuy ➝ Buy$33.00 ➝ $27.00
5/9/2024CitigroupLower TargetBuy ➝ Buy$30.19 ➝ $30.00
5/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$37.00
5/9/2024Stifel NicolausLower TargetHold ➝ Hold$26.00 ➝ $21.00
5/9/2024Robert W. BairdLower TargetOutperform ➝ Outperform$31.00 ➝ $28.00
5/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$30.00
5/9/2024MizuhoLower TargetNeutral ➝ Neutral$25.00 ➝ $21.00
5/6/2024OppenheimerReiterated RatingMarket Perform ➝ Market Perform$19.00 ➝ $19.00
4/30/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$37.00
4/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$37.00
4/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$32.00
3/25/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$29.00 ➝ $25.00
3/13/2024Morgan StanleyLower TargetOverweight ➝ Overweight$40.00 ➝ $30.00
3/12/2024Needham & Company LLCLower TargetBuy$36.00 ➝ $32.00
3/12/2024MizuhoDowngradeBuy ➝ Neutral$39.00 ➝ $25.00
3/1/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$32.00 ➝ $29.00
2/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$33.00
2/28/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$42.00
2/28/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$36.00 ➝ $35.00
2/28/2024MizuhoLower TargetBuy ➝ Buy$40.00 ➝ $39.00
2/28/2024Needham & Company LLCLower TargetBuy ➝ Buy$37.00 ➝ $36.00
2/7/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$42.00
2/5/2024OppenheimerReiterated RatingMarket Perform ➝ Market Perform$25.00
2/2/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$42.00
1/30/2024Robert W. BairdInitiated CoverageOutperform$40.00
1/24/2024Needham & Company LLCUpgradeHold ➝ Buy$37.00
12/29/2023MizuhoBoost TargetBuy ➝ Buy$35.00 ➝ $40.00
12/19/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$31.00 ➝ $40.00
12/18/2023Stifel NicolausBoost TargetHold ➝ Hold$25.00 ➝ $27.00
12/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$42.00
12/13/2023CitigroupInitiated CoverageBuy$38.00
12/12/2023Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$25.00
11/6/2023MizuhoUpgradeNeutral ➝ Buy$20.00 ➝ $35.00
11/3/2023JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$39.00 ➝ $42.00
11/3/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$32.00 ➝ $33.00
11/3/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$30.00 ➝ $31.00
10/17/2023UBS GroupInitiated CoverageBuy$33.00
10/10/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$29.00 ➝ $32.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$42.00
8/7/2023JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$28.00 ➝ $29.00
8/3/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$30.00
8/3/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$39.00 ➝ $38.00
8/3/2023HC WainwrightReiterated RatingBuy ➝ Buy$33.00
8/3/2023OppenheimerReiterated RatingMarket Perform ➝ Market Perform$25.00
7/28/2023OppenheimerBoost Target$23.00 ➝ $25.00
7/17/2023Cantor FitzgeraldBoost Target$36.00 ➝ $42.00
7/17/2023JPMorgan Chase & Co.Boost Target$21.00 ➝ $28.00
7/14/2023CitigroupBoost TargetNeutral$21.60 ➝ $27.00
7/14/2023Morgan StanleyBoost TargetEqual Weight$21.00 ➝ $30.00
7/14/2023Royal Bank of CanadaBoost TargetOutperform$28.00 ➝ $33.00
7/14/2023HC WainwrightBoost TargetBuy$28.00 ➝ $33.00
7/14/2023OppenheimerBoost TargetMarket Perform$20.00 ➝ $23.00
7/14/2023JMP SecuritiesBoost TargetMarket Outperform$31.00 ➝ $39.00
6/15/2023Bank of AmericaBoost Target$26.00 ➝ $29.00
6/14/2023JMP SecuritiesBoost TargetMarket Outperform$23.00 ➝ $31.00
5/22/2023Bank of AmericaBoost Target$23.00 ➝ $26.00
5/9/2023JMP SecuritiesBoost TargetOutperform$22.00 ➝ $23.00
5/9/2023CitigroupBoost Target$21.00 ➝ $21.60
4/28/2023Credit Suisse GroupBoost Target$93.00 ➝ $95.00
4/14/2023MizuhoReiterated RatingNeutral$20.00
3/14/2023Canaccord Genuity GroupBoost TargetBuy$24.00 ➝ $26.00
3/14/2023Royal Bank of CanadaReiterated RatingOutperform$27.00
3/14/2023Morgan StanleyBoost TargetEqual Weight$19.00 ➝ $20.00
3/14/2023GuggenheimBoost Target$22.00 ➝ $25.00
3/14/2023Jefferies Financial GroupBoost Target$10.00 ➝ $15.00
3/14/2023MizuhoBoost Target$19.00 ➝ $20.00
3/14/2023Cantor FitzgeraldBoost TargetOverweight$28.00 ➝ $33.00
3/14/2023CitigroupBoost TargetNeutral$19.40 ➝ $21.00
3/14/2023HC WainwrightBoost TargetBuy$25.00 ➝ $28.00
3/13/2023MizuhoReiterated RatingNeutral$19.00
3/1/2023OppenheimerBoost TargetMarket Perform$17.00 ➝ $20.00
2/28/2023CitigroupBoost TargetNeutral$19.00 ➝ $19.40
2/28/2023JMP SecuritiesLower TargetMarket Perform$24.00 ➝ $22.00
2/28/2023HC WainwrightReiterated RatingBuy$25.00
2/28/2023Morgan StanleyBoost TargetEqual Weight$18.00 ➝ $19.00
2/28/2023Royal Bank of CanadaBoost TargetOutperform$19.00 ➝ $27.00
2/28/2023MizuhoBoost TargetNeutral$15.00 ➝ $19.00
2/15/2023OppenheimerBoost TargetMarket Perform$16.00 ➝ $17.00
1/31/2023CitigroupBoost TargetNeutral$17.00 ➝ $19.00
1/3/2023GuggenheimUpgradeNeutral ➝ Buy$22.00
12/21/2022MizuhoLower TargetNeutral$17.00 ➝ $15.00
11/14/2022JPMorgan Chase & Co.Lower TargetOverweight$19.00 ➝ $17.00
11/3/2022The Goldman Sachs GroupDowngradeNeutral ➝ Sell$15.00 ➝ $12.00
11/3/2022Royal Bank of CanadaLower TargetOutperform$22.00 ➝ $21.00
11/1/2022Loop CapitalInitiated CoverageHold$17.00
10/18/2022HC WainwrightReiterated RatingBuy$25.00
10/13/2022MizuhoLower Target$17.00
10/7/2022MizuhoLower Target$19.00 ➝ $17.00
8/9/2022Morgan StanleyLower TargetEqual Weight$22.00 ➝ $18.00
8/9/2022The Goldman Sachs GroupLower TargetNeutral$20.00 ➝ $15.00
8/9/2022Royal Bank of CanadaLower TargetOutperform$26.00 ➝ $21.00
8/9/2022MizuhoLower TargetNeutral$27.00 ➝ $19.00
8/9/2022HC WainwrightBoost TargetBuy$20.00 ➝ $25.00
8/9/2022CitigroupBoost Target$15.00 ➝ $17.00
8/9/2022Leerink PartnersLower TargetOutperform$27.00 ➝ $21.00
8/8/2022CowenLower TargetOutperform$32.00 ➝ $21.00
8/8/2022CowenLower TargetOutperform$32.00 ➝ $21.00
8/5/2022CitigroupDowngradeBuy ➝ Neutral$19.00 ➝ $15.00
7/15/2022Morgan StanleyLower TargetEqual Weight$24.00 ➝ $22.00
7/11/2022Leerink PartnersLower TargetOutperform$31.00 ➝ $27.00
6/22/2022Canaccord Genuity GroupLower Target$31.00 ➝ $20.00
6/22/2022CitigroupLower TargetBuy$32.00 ➝ $19.00
6/21/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
6/21/2022Jefferies Financial GroupDowngradeBuy ➝ Underperform$25.00 ➝ $10.00
6/21/2022Royal Bank of CanadaLower TargetOutperform$32.00 ➝ $26.00
6/21/2022OppenheimerLower TargetMarket Perform$23.00 ➝ $19.00
6/21/2022Cantor FitzgeraldLower TargetOverweight$37.00 ➝ $26.00
6/21/2022HC WainwrightLower TargetBuy$36.00 ➝ $20.00
6/16/2022Jefferies Financial GroupUpgradeHold ➝ Buy$25.00
4/19/2022MizuhoLower TargetNeutral$28.00 ➝ $27.00
3/18/2022Morgan StanleyReiterated RatingHold$24.00
3/16/2022Canaccord Genuity GroupUpgradeHold ➝ Buy$30.00 ➝ $31.00
3/10/2022Cantor FitzgeraldBoost TargetOverweight$32.00 ➝ $37.00
3/7/2022The Goldman Sachs GroupLower TargetNeutral$27.00 ➝ $24.00
3/3/2022MizuhoLower TargetNeutral$33.00 ➝ $28.00
3/1/2022JMP SecuritiesLower TargetMarket Outperform$42.00 ➝ $35.00
3/1/2022CitigroupBoost Target$30.00 ➝ $32.00
2/9/2022HC WainwrightUpgradeNeutral ➝ Buy$18.00 ➝ $36.00
1/5/2022CitigroupUpgradeNeutral ➝ Buy$30.00
12/23/2021Leerink PartnersReiterated RatingBuy
12/21/2021Bank of AmericaBoost TargetNeutral$28.00 ➝ $32.00
12/21/2021CitigroupBoost TargetNeutral$28.00 ➝ $30.00
12/21/2021Royal Bank of CanadaBoost TargetOutperform$32.00 ➝ $34.00
12/21/2021JMP SecuritiesBoost TargetMarket Outperform$39.00 ➝ $42.00
12/21/2021GuggenheimDowngradeBuy ➝ Neutral$28.00
12/21/2021MizuhoReiterated RatingHold
12/8/2021The Goldman Sachs GroupBoost TargetNeutral$25.00 ➝ $28.00
12/7/2021Morgan StanleyBoost TargetEqual Weight$21.00 ➝ $24.00
12/7/2021OppenheimerBoost TargetMarket Perform$20.00 ➝ $23.00
12/7/2021JMP SecuritiesBoost TargetOutperform ➝ Market Outperform$35.00 ➝ $39.00
12/7/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$27.00 ➝ $31.00
12/7/2021CitigroupBoost TargetNeutral$25.00 ➝ $28.00
12/7/2021MizuhoBoost TargetNeutral$24.00 ➝ $26.00
11/9/2021CitigroupBoost TargetNeutral$22.00 ➝ $25.00
11/1/2021GuggenheimUpgradeNeutral ➝ Buy$19.00 ➝ $23.00
10/14/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$17.00 ➝ $20.00
8/5/2021Needham & Company LLCLower TargetBuy$30.00 ➝ $26.00
8/5/2021Morgan StanleyLower TargetOverweight$29.00 ➝ $27.00
8/5/2021Leerink PartnersLower TargetOutperform$31.00 ➝ $28.00
8/5/2021Cantor FitzgeraldLower TargetOverweight$33.00 ➝ $27.00
7/19/2021Leerink PartnersReiterated RatingOutperform
7/10/2021Raymond JamesSet Target$23.71
7/9/2021Raymond JamesReiterated RatingHold
6/10/2021Berenberg BankInitiated CoverageHold$29.00
5/6/2021Morgan StanleyBoost TargetOverweight$28.00 ➝ $29.00
5/6/2021MizuhoReiterated RatingHold
4/13/2021The Goldman Sachs GroupReiterated RatingBuy ➝ Neutral$73.00 ➝ $25.00
4/13/2021Jefferies Financial GroupReiterated RatingBuy ➝ Hold$40.00 ➝ $21.00
4/13/2021MizuhoReiterated RatingBuy ➝ Neutral$25.00
4/13/2021HC WainwrightReiterated RatingBuy ➝ Neutral$43.00 ➝ $18.00
4/7/2021HC WainwrightDowngradeBuy ➝ Neutral$43.00 ➝ $18.00
4/6/2021Leerink PartnersLower TargetOutperform$63.00 ➝ $31.00
4/6/2021Morgan StanleyLower TargetOverweight$50.00 ➝ $28.00
4/6/2021Cantor FitzgeraldBoost TargetOverweight$33.00 ➝ $45.00
4/6/2021MizuhoDowngradeBuy ➝ Neutral$37.00 ➝ $25.00
4/6/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$40.00 ➝ $21.00
4/5/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$73.00 ➝ $25.00
4/5/2021Raymond JamesDowngradeOutperform ➝ Market Perform
4/5/2021Needham & Company LLCLower TargetBuy$44.00 ➝ $30.00
3/16/2021Bank of AmericaReiterated RatingBuy ➝ Neutral
3/15/2021Stifel NicolausReiterated RatingBuy ➝ Hold$68.00 ➝ $27.00
3/15/2021Raymond JamesReiterated RatingStrong-Buy ➝ Outperform$65.00 ➝ $35.00
3/15/2021GuggenheimReiterated RatingBuy ➝ Neutral
3/15/2021CitigroupReiterated RatingBuy ➝ Neutral$66.00 ➝ $35.00
3/10/2021Bank of AmericaDowngradeBuy ➝ Neutral
3/9/2021GuggenheimDowngradeBuy ➝ Neutral
3/9/2021Morgan StanleyLower TargetOverweight$65.00 ➝ $50.00
3/9/2021CowenLower TargetOutperform$66.00 ➝ $57.00
3/9/2021OppenheimerLower TargetMarket Perform$42.00 ➝ $28.00
3/9/2021CitigroupDowngradeBuy ➝ Neutral$66.00 ➝ $35.00
3/9/2021Needham & Company LLCLower TargetBuy$60.00 ➝ $44.00
3/9/2021MizuhoLower TargetBuy$70.00 ➝ $55.00
3/9/2021HC WainwrightLower TargetBuy$60.00 ➝ $43.00
3/9/2021Royal Bank of CanadaLower TargetOutperform$60.00 ➝ $36.00
3/9/2021Stifel NicolausDowngradeBuy ➝ Hold$68.00 ➝ $27.00
3/9/2021Raymond JamesDowngradeStrong-Buy ➝ Outperform$65.00 ➝ $35.00
3/2/2021Royal Bank of CanadaBoost TargetOutperform$55.00 ➝ $63.00
2/25/2021Morgan StanleyBoost TargetOverweight$60.00 ➝ $65.00
2/24/2021MizuhoReiterated RatingBuy$69.00 ➝ $70.00
12/29/2020Cantor FitzgeraldReiterated RatingOverweight$61.00 ➝ $70.00
12/16/2020Morgan StanleyBoost TargetOverweight$58.00 ➝ $60.00
12/15/2020MizuhoInitiated CoverageBuy$69.00
11/16/2020Raymond JamesUpgradeOutperform ➝ Strong-Buy$65.00
11/5/2020Morgan StanleyBoost TargetOverweight$57.00 ➝ $58.00
10/13/2020Morgan StanleyBoost TargetOverweight$55.00 ➝ $57.00
8/24/2020Raymond JamesInitiated CoverageOutperform$65.00
8/20/2020Morgan StanleyInitiated CoverageOverweight$55.00
8/6/2020HC WainwrightReiterated RatingBuy
8/6/2020Needham & Company LLCReiterated RatingBuy$60.00
8/6/2020Leerink PartnersLower TargetOutperform$56.00 ➝ $52.00
8/6/2020OppenheimerReiterated RatingHold$42.00
7/21/2020Jefferies Financial GroupReiterated RatingBuy$60.00
7/21/2020CitigroupLower Target$69.00 ➝ $63.00
7/21/2020Cantor FitzgeraldLower TargetOverweight$63.00 ➝ $61.00
7/21/2020OppenheimerLower TargetPositive ➝ Market Perform$53.00 ➝ $42.00
7/21/2020Royal Bank of CanadaLower TargetOutperform$61.00 ➝ $55.00
7/16/2020Needham & Company LLCInitiated CoverageBuy$60.00
7/9/2020Royal Bank of CanadaBoost TargetPositive ➝ Outperform$58.00 ➝ $61.00
7/6/2020Stifel NicolausUpgradeHold ➝ Buy$41.00 ➝ $71.00
5/27/2020OppenheimerBoost TargetMarket Perform$48.00 ➝ $53.00
5/8/2020JPMorgan Chase & Co.Boost TargetOverweight$50.00 ➝ $55.00
5/8/2020OppenheimerReiterated RatingHold$48.00
5/8/2020Cantor FitzgeraldBoost TargetBuy$58.00 ➝ $63.00
5/8/2020Needham & Company LLCReiterated RatingBuy
4/16/2020Jefferies Financial GroupInitiated CoverageBuy$60.00
3/31/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$45.00 ➝ $72.00
3/5/2020CitigroupInitiated CoverageBuy$69.00
3/5/2020CowenReiterated RatingBuy$66.00
2/27/2020HC WainwrightReiterated RatingBuy$60.00
2/27/2020Cantor FitzgeraldReiterated RatingOverweight$70.00 ➝ $75.00
2/26/2020JPMorgan Chase & Co.Set TargetOutperform$50.00
1/19/2020JPMorgan Chase & Co.Reiterated RatingBuy
1/14/2020CowenReiterated RatingBuy$66.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.01 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 16 very positive mentions
  • 18 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
Mentions as of
5/25/2024
  • 13 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 10 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 17 very positive mentions
  • 26 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 14 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 16 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 16 very positive mentions
  • 19 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 22 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 22 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

ACADIA Pharmaceuticals logo
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $16.87
Low: $16.49
High: $17.21

50 Day Range

MA: $16.24
Low: $14.29
High: $18.76

52 Week Range

Now: $16.87
Low: $14.15
High: $32.59

Volume

4,937,927 shs

Average Volume

1,682,364 shs

Market Capitalization

$2.81 billion

P/E Ratio

21.63

Dividend Yield

N/A

Beta

0.4

Frequently Asked Questions

What sell-side analysts currently cover shares of ACADIA Pharmaceuticals?

The following equities research analysts have issued stock ratings on ACADIA Pharmaceuticals in the last year: Bank of America Co., BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., HC Wainwright, JMP Securities, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Raymond James, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, TheStreet, and UBS Group AG.
View the latest analyst ratings for ACAD.

What is the current price target for ACADIA Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for ACADIA Pharmaceuticals in the last year. Their average twelve-month price target is $25.60, suggesting a possible upside of 51.7%. JMP Securities has the highest price target set, predicting ACAD will reach $42.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $19.00 for ACADIA Pharmaceuticals in the next year.
View the latest price targets for ACAD.

What is the current consensus analyst rating for ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals currently has 6 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ACAD.

What other companies compete with ACADIA Pharmaceuticals?

Other companies that are similar to ACADIA Pharmaceuticals include Catalent, Vaxcyte, Qiagen, Intra-Cellular Therapies and Roivant Sciences. Learn More about companies similar to ACADIA Pharmaceuticals.

How do I contact ACADIA Pharmaceuticals' investor relations team?

ACADIA Pharmaceuticals' physical mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company's listed phone number is (858) 558-2871 and its investor relations email address is [email protected]. The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com. Learn More about contacing ACADIA Pharmaceuticals investor relations.